Csenge Advisory Group Buys 432 Shares of Novartis AG $NVS

Csenge Advisory Group increased its stake in Novartis AG (NYSE:NVS) by 2.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,408 shares of the company’s stock after buying an additional 432 shares during the period. Csenge Advisory Group’s holdings in Novartis were worth $2,131,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. WPG Advisers LLC bought a new position in shares of Novartis in the 1st quarter worth approximately $25,000. GFG Capital LLC bought a new position in Novartis in the second quarter worth $26,000. Barrett & Company Inc. bought a new position in Novartis in the second quarter worth $31,000. MCF Advisors LLC raised its holdings in Novartis by 66.0% in the second quarter. MCF Advisors LLC now owns 264 shares of the company’s stock worth $32,000 after purchasing an additional 105 shares in the last quarter. Finally, Investment Management Corp VA ADV raised its holdings in Novartis by 172.2% in the first quarter. Investment Management Corp VA ADV now owns 313 shares of the company’s stock worth $35,000 after purchasing an additional 198 shares in the last quarter. 13.12% of the stock is owned by institutional investors.

Novartis Stock Up 0.4%

NYSE:NVS opened at $125.47 on Thursday. The firm has a market cap of $265.05 billion, a P/E ratio of 17.14, a P/E/G ratio of 1.93 and a beta of 0.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.62 and a current ratio of 0.88. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $133.55. The firm has a 50-day simple moving average of $127.29 and a two-hundred day simple moving average of $120.51.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing the consensus estimate of $2.26 by ($0.01). The firm had revenue of $13.91 billion for the quarter, compared to the consensus estimate of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. Novartis’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the business earned $2.06 EPS. Analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on NVS shares. The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 price target (down from $119.00) on shares of Novartis in a research note on Friday, September 12th. Wall Street Zen downgraded shares of Novartis from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 1st. HC Wainwright downgraded shares of Novartis to a “neutral” rating in a research note on Monday, October 27th. Morgan Stanley raised shares of Novartis from an “equal weight” rating to an “overweight” rating in a research note on Friday, October 31st. Finally, Cfra set a $126.00 price objective on Novartis and gave the company a “hold” rating in a research report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and a consensus target price of $122.33.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.